๐ข Recruiting
Phase 2
๐ Investigational Drug / Biologic
NCT06050694
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
๐ Princess Margaret Cancer Centre โ Toronto, Ontario
View Study & Checklist โ